EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial

Ravin Ratan iD, Bernd Kasper iD, Thierry Alcindor iD, Patrick Schöffski iD, Winette T A van der Graaf iD, Noah Federman, Nam Q Bui iD, Gina D'Amato, Richard F Riedel iD, Steven Attia iD, Sant Chawla, Allison Lim iD und 5 weitere

Journal of Clinical Oncology · 2025-12 · 43 (34) · 3646-3651

DOI: 10.1200/jco-25-00582 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-12. Verfasst von Ravin Ratan und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, Houston, TX. Hauptthemen laut MEDLINE: Desmoid Tumors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964 ) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PRO) in adult patients with progressing desmoid tumors (DT; median [range] exposure: 20.6 [0.3-33.6] months). Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024. End points included PFS and ORR per RECIST v1.1, PRO, and safety. The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis. Further target tumor size reduction occurred in most patients. Benefits in PROs were sustained while on treatment. Frequently reported treatment-emergent adverse events (TEAEs) decreased in incidence and severity over time. Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4. In conclusion, long-term continuous nirogacestat treatment was associated with further tumor size reductions, durable objective responses, sustained PRO benefits, and a manageable safety profile consistent with the primary analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desmoid TumorsHumansFemaleMaleAdultMiddle AgedAgedYoung AdultProgression-Free SurvivalPatient Reported Outcome Measures

Autor:innen und Institutionen

  • University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, Houston, TX.
  • University of Heidelberg; Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit, Mannheim, Germany.
  • Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA.

ORCID-Profile: Ravin Ratan, Bernd Kasper, Thierry Alcindor, Patrick Schöffski, Winette T A van der Graaf, Nam Q Bui, Richard F Riedel, Steven Attia, Allison Lim, Brad Tumminello, Mrinal Gounder

Förderung

  • NCI NIH HHS

Zitieren

APA

Ratan, R., Kasper, B., Alcindor, T., Schöffski, P., van der Graaf, W. T. A., Federman, N., Bui, N. Q., D'Amato, G., Riedel, R. F., Attia, S., Chawla, S., Lim, A., Tumminello, B., Oton, A. B., Chu, Y., Zhou, S., & Gounder, M. (2025). Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial. Journal of Clinical Oncology, 43(34), 3646-3651. https://doi.org/10.1200/jco-25-00582

Vancouver

Ratan R, Kasper B, Alcindor T, Schöffski P, van der Graaf WTA, Federman N, et al. Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial. Journal of Clinical Oncology. 2025;43(34):3646-3651. doi:10.1200/jco-25-00582

BibTeX
@article{Ratan2025,
  author = {Ratan, Ravin and Kasper, Bernd and Alcindor, Thierry and Schöffski, Patrick and van der Graaf, Winette T A and Federman, Noah and Bui, Nam Q and D'Amato, Gina and Riedel, Richard F and Attia, Steven and Chawla, Sant and Lim, Allison and Tumminello, Brad and Oton, Ana B and Chu, Yucheng and Zhou, Shengfan and Gounder, Mrinal},
  title = {Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {34},
  pages = {3646--3651},
  doi = {10.1200/jco-25-00582}
}
Kostenlos starten →